证券代码：600829 证券简称：人民同泰 编号：临 2024-017 哈药集团人民同泰医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●哈药集团人民同泰医药股份有限公司（以下简称"公司"）股票于 2024 年 12 月 12 日、2024 年 12 月 13 日连续 2 个交易日内日收盘价格涨幅偏离值累计超过 20%，属于《上海 证券交易所交易规则》规定的股票交易异常波动情形。 ●经公司自查，并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限 公司询证，不存在应披露而未披露的重大事项或重要信息。 ●敬请广大投资者注意二级市场交易风险，理性投资。 一、股票交易异常波动的具体情况 公司股票于2024年12月12日、2024年12月13日连续2个交易日内日收盘价格 涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于 股票交易异常波动情况。 二、公司关注并核实的相关情况 （一）经公司自查，公司目前经营活动正常；公司不存在其他应披露而未披 露的重 ...

一、截止目前,本公司及本公司各方股东均不存在应披露而未披 露的影响贵公司股价异常波动的重大信息,包括但不限于重大资产重 组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、 破产重整、重大业务合作、引进战略投资者等重大事项。 股票交易异常波动询证函的回复 哈药集团人民同泰医药股份有限公司： 贵公司股票于 2024年 12月 12日、2024年 12月 13 日连续两个 交易日内日收盘价格涨幅偏离值累计超过 20%。贵公司发来的《哈药 集团人民同泰医药股份有限公司关于股票交易异常波动的询证函》已 收悉,针对函件所列问题,我公司回复如下: 哈药集团有限公司 关于哈药集团人民同泰医药股份有限公司 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股 票的情形。 特此回复。 ...

哈药集团股份有限公司 关于哈药集团人民同泰医药股份有限公司股票交易异常波 动淘证函的回复 . 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股 票的情况。 特此回复。 本页无正文,为《哈药集团股份有限公司关于哈药集团人民同泰医药 股份有限公司股票交易异常波动询证函的回复》之盖章页: 哈兹 笙闭股份有限公同 H rest and 哈药集团人民同泰医药股份有限公司: 贵公司股票于 2024 年 12 月 12 日、2024 年 12 月 13 日连续两个 交易日内日收盘价格涨幅偏离值累计超过20%,按照《上海证券交易 所交易规则》的有关规定,属于股票交易异常波动情况。贵公司发来 的《哈药集团人民同泰医药股份有限公司关于股票交易异常波动的询 证函》已收悉。针对函件所列问题,我公司回复如下: 一、本公司不存在任何应披露而未披露的影响贵公司股价异常波 动的重大信息,包括但不限于重大资产重组、股份发行、重大交易类 事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 ...

Company Overview - The company primarily engages in pharmaceutical wholesale, retail, logistics, and medical services [2] - In the first three quarters of 2024, the company achieved a revenue of CNY 7.678 billion, a year-on-year decrease of 1.88% [2] - The net profit for the same period was CNY 206 million, down 14.36% year-on-year [2] Market Position - The company holds a market share of approximately 40% in the pharmaceutical distribution sector within Heilongjiang Province [2] - Its wholesale business extends to Jilin and Inner Mongolia, covering three major terminals and six markets [2] Business Strategy - The company is focusing on enhancing its market share through innovation in treatment drugs and strengthening grassroots medical delivery services [2] - It aims to improve channel value by enhancing professional service levels and increasing access to medical device terminals [2] Financial Performance - The gross profit margin for the medical distribution business in 2023 was 8.29%, an increase of 0.84% year-on-year [3] - The reduction in financial expenses by 44.96% in 2023 was achieved through expanding financing channels and optimizing the capital structure [3] Policy Impact - The company is closely monitoring national policy changes, particularly those affecting drug pricing, prescription flow, and payment structures [3] - It is committed to compliance and adapting its business model in response to policy opportunities [3] Accounts Receivable Management - The company has implemented a credit management system and repayment plans to enhance accounts receivable management [3]

Financial Performance - The company's operating revenue for Q3 2024 was CNY 2,692,555,665.17, representing a year-on-year increase of 5.60%[2] - The net profit attributable to shareholders for Q3 2024 was CNY 70,812,457.93, a decrease of 18.79% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 69,476,122.14, down 14.51% year-on-year[2] - The company reported a decrease in net profit for the first three quarters of 2024 to CNY 20,600,428.00, down 14.36% year-on-year[3] - Total operating revenue for the first three quarters of 2024 was CNY 7,678,084,114.44, a decrease of 1.87% compared to CNY 7,824,968,820.09 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 206,004,237.80, compared to CNY 240,631,596.05 in the same period of 2023, representing a decline of 14.36%[18] - Earnings per share for the first three quarters of 2024 were CNY 0.3552, down from CNY 0.4148 in the same period of 2023[19] Assets and Liabilities - The total assets at the end of Q3 2024 were CNY 7,030,986,779.54, a decrease of 5.33% from the end of the previous year[3] - As of September 30, 2024, the total current assets amounted to approximately CNY 6.54 billion, a decrease of 5.54% from CNY 6.92 billion at the end of 2023[12] - Total liabilities as of September 30, 2024, were approximately CNY 4.01 billion, a decrease of 11.2% from CNY 4.52 billion[14] - The total assets amounted to approximately CNY 7.03 billion, down from CNY 7.43 billion, reflecting a decrease of 5.5%[14] - Total liabilities as of the end of the third quarter of 2024 were CNY 4,157,082,054.96, down from CNY 4,675,089,264.47 at the end of the third quarter of 2023[15] Cash Flow - The net cash flow from operating activities for the first three quarters was -CNY 24,329,640.00, a decrease of CNY 39,884,200.00 year-on-year[4] - Cash flow from operating activities for the first three quarters of 2024 was CNY 7,473,195,117.41, a decrease from CNY 7,611,384,554.59 in 2023[20] - The net cash flow from operating activities was -243,296,367.64 RMB, a decrease from 155,545,592.71 RMB in the previous period[22] - The total cash inflow from financing activities was 690,000,000.00 RMB, down from 865,800,000.00 RMB in the previous period[22] - Cash and cash equivalents at the end of the period totaled 733,996,899.23 RMB, compared to 948,782,611.98 RMB at the end of the previous period[23] Operational Efficiency - The gross profit margin decreased due to a higher proportion of lower-margin DTP products sold in the retail segment[3] - The company reported a decrease in sales expenses to CNY 295,298,616.51 from CNY 314,819,920.84 in the previous year, a reduction of 6.23%[18] - The company experienced a 39.45% decrease in cash and cash equivalents year-to-date due to reduced operating cash flow and dividend payments[6] - The company reported a decrease in management expenses from ¥2,273,621.40 in 2023 to ¥1,986,736.86 in 2024, a reduction of approximately 12.6%[28] Future Plans and Strategies - The company plans to enhance its DTP pharmacy development and improve employee service capabilities to drive retail sales growth[3] - The company has not indicated any new product launches or significant market expansion strategies in the current report[31] Shareholder Information - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[10] - There are no known relationships or concerted actions among the top ten shareholders[10]

Group 1: Company Overview - The company is primarily engaged in pharmaceutical wholesale, retail, and related services [1] - The company has a development history, main business operations, and a management team that were introduced during the investor meeting [1] Group 2: Financial Performance - In the first half of 2024, the company achieved a revenue of CNY 4.986 billion, representing a growth of 5.49% [1] - The net profit for the same period was CNY 135 million, showing a year-on-year decline of 11.84% [1] Group 3: Business Development - The company currently operates 15 DTP (Direct-to-Patient) specialty pharmacies in Heilongjiang Province, focusing on oncology and immunotherapy medications [1] - The growth in the retail segment is primarily attributed to the expansion of the DTP business [1]

证券代码：600829 证券简称：人民同泰 哈药集团人民同泰医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|--------|------------| | | | | | | 编号： | 2024-002 | | | | □特定对象调研 | ...

证券代码：600829 证券简称：人民同泰 编号：临 2024-016 哈药集团人民同泰医药股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 9 月 18 日（星期三）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssein fo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2024 年 9 月 9 日（星期一）-2024 年 9 月 13 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱：renmintongtai@hyr mtt.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 哈药集团人民同泰医药股份有限公司（以下简称"公司"）已于 2024 年 8 月 9 日披露了《2024 年半年度报告》。为进一步加强与投资者的互动交流，便于 广大投资者更全面深入了解公司 2024 年 ...

本页无正文，为《哈药集团股份有限公司关于哈药集团人民同泰医药 股份有限公司股票交易异常波动问询函的回复》之盖章页: 哈 闭股价有限 六百 『年九月九日 哈药集团股份有限公司 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股 票的情况。 关于哈药集团人民同泰医药股份有限公司股票交易异常波 动间询函的回复 特此回复。 哈药集团人民同泰医药股份有限公司: 贵公司股票于 2024 年 9 月 4 日、2024 年 9 月 5 日连续两个交易 日内日收盘价格涨幅偏离值累计超过 20%,按照《上海证券交易所交 易规则》的有关规定,属于股票交易异常波动情况。贵公司发来的《哈 药集团人民同泰医药股份有限公司关于股票交易异常波动的问询函》 已收悉。针对函件所列问题,我公司回复如下： 一、本公司不存在任何应披露而未披露的影响贵公司股价异常波 动的重大信息,包括但不限于重大资产重组、股份发行、重大交易类 事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 ...

证券代码：600829 证券简称：人民同泰 编号：临 2024-015 哈药集团人民同泰医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●哈药集团人民同泰医药股份有限公司（以下简称"公司"）股票于 2024 年 9 月 4 日、 9 月 5 日连续 2 个交易日内日收盘价格涨幅偏离值累计超过 20%，属于《上海证券交易所交 易规则》规定的股票交易异常波动情形。 ●经公司自查，并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限 公司核实，不存在应披露而未披露的重大事项或重要信息。 ●敬请广大投资者注意二级市场交易风险，理性投资。 （二）经向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有 限公司征询确认，本公司控股股东、间接控股股东及间接控股股东的各方股东均 不存在应披露而未披露的影响公司股价异常波动的重大信息，包括但不限于重大 资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、破产 重整、重大业务合作、引进战略投资者等重大事项。 一、股 ...